Google
Trusted Resources: News & Events
Latest announcements and gatherings
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell Disease
Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy designed to address the underlying pathology of sickle cell disease (SCD). In preclinical studies, IMR-687’s mechanism of action was shown to positively impact both red and white blood cell pathologies associated with the disease. The company has previously reported the ability of IMR-687 to induce fetal hemoglobin (HbF) in murine and human cells at ASH in 2017. Importantly, the data from a recent Phase 1 clinical trial in healthy volunteers demonstrated IMR-687 to be safe and well-tolerated at the target dose that exceeded the effective doses in cell and animal models of SCD, thereby clearing a path to a Phase 2 study in adult patients with SCD. The new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference in New York.
+myBinderRelated Content
-
California Institute For Regenerative Medicine Awards City Of Hope $5.74 Million For Severe Sickle Cell Disease Clin...The California Institute for Regenerativ...
-
The Influence of Perceived Racial Bias and Health-Related Stigma on Quality of Life Among Children With Sickle Cell ...Objectives: Individuals with sickle ce...
-
A Child Prodigy, a Painful Disease, and a Life-Changing Treatmenthttps://www.youtube.com/watch?v=SpzjD1ct...
-
UH BEATS programhttps://www.youtube.com/watch?v=lzvl_tyv...
-
Nutrition for the Child with Sickle Cell AnemiaSickle Cell Disease (SCD), also called S...
-
Matthew Porteus awarded grant for sickle cell anemia workThe California Institute for Regenerativ...
-
University Hospitals program uses music to teach about sickle cell (photos, video)The study looked at Seidman's BEATS (Bui...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.